Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis (pages 313–321)
Dr. Lluís Ballell, Dr. Robert H. Bates, Dr. Rob J. Young, Daniel Alvarez-Gomez, Dr. Emilio Alvarez-Ruiz, Vanessa Barroso, Delia Blanco, Benigno Crespo, Dr. Jaime Escribano, Rubén González, Sonia Lozano, Dr. Sophie Huss, Angel Santos-Villarejo, Dr. José Julio Martín-Plaza, Dr. Alfonso Mendoza, Dr. María José Rebollo-Lopez, Dr. Modesto Remuiñan-Blanco, Dr. José Luis Lavandera, Dr. Esther Pérez-Herran, Dr. Francisco Javier Gamo-Benito, Dr. José Francisco García-Bustos, Dr. David Barros, Dr. Julia P. Castro and Dr. Nicholas Cammack
Article first published online: 10 JAN 2013 | DOI: 10.1002/cmdc.201200428
Needles from the haystack: As part of GlaxoSmithKline's commitment to open innovation research against neglected diseases such as TB, herein we report the results of a high-throughput phenotypic screen of two million compounds. A set of 177 potent, non-cytotoxic hits against Mycobacterium tuberculosis H37Rv are described. Samples of these compounds will be made available in an effort to promote further research against this critical disease.